Media Centre
.jpg/_jcr_content/renditions/cq5dam.web.620.AZ1582_Circulating_tumour_DNA,P20,282,29.jpg.pagespeed.ce.5L1wtUiPmc.jpg)
AstraZeneca H1 2017 Results
Media Teleconference – Thursday 27 July 2017
AstraZeneca will announce its H1 2017 Results at 07:00 BST on Thursday, 27 July 2017. You are invited to participate in a media teleconference hosted by Pascal Soriot, CEO, to discuss the results at 09:00 BST.
Conference detailsLatest press releases
-
Kyntheum approved in the EU for the treatment of adults with moderate-to-severe plaque psoriasis
-
Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer
-
AstraZeneca presents new data underpinning safety profile and real-world CV outcomes of Farxiga at ADA 2017
-
AstraZeneca to present scientific advances in cardiovascular and metabolic diseases at 2017 ADA Scientific Sessions
-
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Esra Erkal-Paler
Global Head of External Communications
Karen Birmingham
Director Global Science Media
Rob Skelding
Director Global Media Relations
Matthew Kent
Director Global Media Relations
Jacob Lund
Director External Communications, Sweden
Lotta Sjösten
Manager Media Relations, Sweden
US Media Team
